Research programme: wound healing therapy - LadRx Corporation
Alternative Names: Wound healing therapy research programme - BiorexLatest Information Update: 29 Sep 2022
Price :
$50 *
At a glance
- Originator Biorex; CytRx Corporation
- Developer Biorex
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chronic wounds
Most Recent Events
- 23 Sep 2022 CytRx Corporation is now called LadRx Corporation
- 05 Dec 2008 Discontinued - Preclinical for Chronic wounds in Hungary (unspecified route)
- 13 Oct 2004 Biorex has been acquired by CytRx Corporation